DE60209010D1 - Chimäre phagen - Google Patents

Chimäre phagen

Info

Publication number
DE60209010D1
DE60209010D1 DE60209010T DE60209010T DE60209010D1 DE 60209010 D1 DE60209010 D1 DE 60209010D1 DE 60209010 T DE60209010 T DE 60209010T DE 60209010 T DE60209010 T DE 60209010T DE 60209010 D1 DE60209010 D1 DE 60209010D1
Authority
DE
Germany
Prior art keywords
phages
protein
phage
helper
coat
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60209010T
Other languages
English (en)
Other versions
DE60209010T2 (de
Inventor
Erwin Houtzager
Ton Logtenberg
Kruif Adriaan De
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Vaccines and Prevention BV
Original Assignee
Crucell Holand BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP01202304A external-priority patent/EP1266963A1/de
Priority claimed from US09/882,621 external-priority patent/US7070926B2/en
Application filed by Crucell Holand BV filed Critical Crucell Holand BV
Publication of DE60209010D1 publication Critical patent/DE60209010D1/de
Application granted granted Critical
Publication of DE60209010T2 publication Critical patent/DE60209010T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/02—Libraries contained in or displayed by microorganisms, e.g. bacteria or animal cells; Libraries contained in or displayed by vectors, e.g. plasmids; Libraries containing only microorganisms or vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/10011—Details dsDNA Bacteriophages
    • C12N2795/10021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/10011—Details dsDNA Bacteriophages
    • C12N2795/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Immunology (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Holo Graphy (AREA)
DE60209010T 2001-06-15 2002-06-14 Chimäre phagen Expired - Lifetime DE60209010T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP01202304 2001-06-15
US882621 2001-06-15
EP01202304A EP1266963A1 (de) 2001-06-15 2001-06-15 Chimäre Phagen
US09/882,621 US7070926B2 (en) 2001-06-15 2001-06-15 Chimaeric phages
PCT/NL2002/000391 WO2002103012A1 (en) 2001-06-15 2002-06-14 Chimaeric phages

Publications (2)

Publication Number Publication Date
DE60209010D1 true DE60209010D1 (de) 2006-04-13
DE60209010T2 DE60209010T2 (de) 2006-09-28

Family

ID=26076931

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60209010T Expired - Lifetime DE60209010T2 (de) 2001-06-15 2002-06-14 Chimäre phagen

Country Status (10)

Country Link
US (2) US7329530B2 (de)
EP (1) EP1402025B1 (de)
AT (1) ATE317009T1 (de)
AU (1) AU2002345421B2 (de)
CA (1) CA2449071C (de)
DE (1) DE60209010T2 (de)
DK (1) DK1402025T3 (de)
ES (1) ES2257560T3 (de)
NZ (1) NZ529465A (de)
WO (1) WO2002103012A1 (de)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7329530B2 (en) 2001-06-15 2008-02-12 Crucell Holland B.V. Chimaeric phages
US7070926B2 (en) 2001-06-15 2006-07-04 Crucell Holland B.V. Chimaeric phages
AU2002349905A1 (en) * 2001-12-17 2003-06-30 Ribapharm Inc. Nucleoside libraries and compounds by mcc combinatorial strategies on solid support
USRE47770E1 (en) 2002-07-18 2019-12-17 Merus N.V. Recombinant production of mixtures of antibodies
NZ537277A (en) 2002-07-18 2008-04-30 Crucell Holland Bv Recombinant production of mixtures of antibodies
US20100069614A1 (en) 2008-06-27 2010-03-18 Merus B.V. Antibody producing non-human mammals
WO2004106375A1 (en) 2003-05-30 2004-12-09 Merus Biopharmaceuticals B.V. I.O. Fab library for the preparation of anti vegf and anti rabies virus fabs
NZ543635A (en) 2003-06-25 2008-05-30 Crucell Holland Bv Human C-type lectin: a suitable target molecule for binding molecules, particularly immunoconjugates, in the diagnosis, prevention and/or treatment of myeloid neoplastic diseases such as AML and CML
PL2314621T3 (pl) 2004-05-27 2014-08-29 Crucell Holland Bv Cząsteczki wiążące zdolne do neutralizowania wirusa wścieklizny i ich zastosowania
JP4852046B2 (ja) 2004-10-12 2012-01-11 クルセル ホランド ベー ヴェー 癌の治療及び検出に用いる結合分子
SG159542A1 (en) 2004-11-11 2010-03-30 Crucell Holland Bv Compositions against sars-coronavirus and uses thereof
CA2591665C (en) 2004-12-20 2015-05-05 Crucell Holland B.V. Binding molecules capable of neutralizing west nile virus and uses thereof
US20060235795A1 (en) * 2005-04-19 2006-10-19 Microsoft Corporation Secure network commercial transactions
CA2608058C (en) 2005-05-12 2013-09-10 Crucell Holland B.V. Host cell specific binding molecules capable of neutralizing viruses and uses thereof
AU2006290736B2 (en) 2005-09-15 2011-09-15 Crucell Holland B.V. Method for preparing immunoglobulin libraries
EP1963494B1 (de) * 2005-11-29 2014-10-08 The Trustees of The University of Pennsylvania Diagnostische phagenpartikelreagentien
EP1960526A4 (de) * 2005-12-07 2009-07-15 Los Alamos Nat Security Llc Plasmide und verpackungszelllinien zur verwendung in einer phagenanzeige
US7960518B2 (en) 2006-06-06 2011-06-14 Crucell Holland B.V. Human binding molecules having killing activity against enterococci and uses thereof
DK2027155T3 (en) 2006-06-06 2016-05-09 Crucell Holland Bv HUMAN BINDING MOLECULES with killer activity against staphylococci and uses thereof
CA2663388C (en) 2006-09-07 2017-01-17 Crucell Holland B.V. Human binding molecules capable of neutralizing influenza virus h5n1 and uses thereof
SG10201607410TA (en) 2006-09-07 2016-10-28 Crucell Holland Bv Human binding molecules capable of neutralizing influenza virus h5n1 and uses thereof
US9150849B2 (en) 2007-11-02 2015-10-06 The Scripps Research Institute Directed evolution using proteins comprising unnatural amino acids
KR101790354B1 (ko) 2009-05-11 2017-10-25 얀센 백신스 앤드 프리벤션 비.브이. 인플루엔자 바이러스 ｈ3ｎ2를 중화시킬 수 있는 인간 결합 분자 및 그것의 용도
EP2731967B1 (de) 2011-07-14 2016-10-12 Janssen Vaccines & Prevention B.V. Humane bindungsmoleküle zur neutralisierung von influenza a-viren der phylogenetischen gruppe 1 und 2 und influenza b-viren
CA2791109C (en) 2011-09-26 2021-02-16 Merus B.V. Generation of binding molecules
MX360056B (es) 2012-03-08 2018-10-19 Janssen Vaccines & Prevention Bv Moléculas de unión humanas que pueden unirse a los virus de la influenza b y neutralizarlos, y sus usos.
WO2013157953A1 (en) 2012-04-20 2013-10-24 Merus B.V. Methods and means for the production of ig-like molecules
CA3003911C (en) * 2015-11-25 2021-05-04 Eli Lilly And Company Phage display vectors and methods of use
WO2020180971A1 (en) * 2019-03-04 2020-09-10 The Texas A&M University System Methods of making and utilizing amber-obligated phage display libraries

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9500851D0 (en) * 1995-01-17 1995-03-08 Bionvent International Ab Method of selecting specific bacteriophages
EP1266963A1 (de) 2001-06-15 2002-12-18 Crucell Holland B.V. Chimäre Phagen
US7329530B2 (en) * 2001-06-15 2008-02-12 Crucell Holland B.V. Chimaeric phages
US7070926B2 (en) 2001-06-15 2006-07-04 Crucell Holland B.V. Chimaeric phages

Also Published As

Publication number Publication date
US7329530B2 (en) 2008-02-12
AU2002345421B2 (en) 2006-11-16
US20090017521A1 (en) 2009-01-15
EP1402025A1 (de) 2004-03-31
EP1402025B1 (de) 2006-02-01
CA2449071A1 (en) 2002-12-27
NZ529465A (en) 2005-05-27
US7901919B2 (en) 2011-03-08
WO2002103012A1 (en) 2002-12-27
ES2257560T3 (es) 2006-08-01
DK1402025T3 (da) 2006-06-06
US20050014261A1 (en) 2005-01-20
CA2449071C (en) 2008-12-16
ATE317009T1 (de) 2006-02-15
DE60209010T2 (de) 2006-09-28

Similar Documents

Publication Publication Date Title
ATE317009T1 (de) Chimäre phagen
NZ513153A (en) Selection of proteins using RNA-protein fusions
ATE384119T1 (de) Isoprenoidproduktion
WO2002004523A3 (en) Artificial antibody polypeptides
AU1548795A (en) Bacterial receptor structures
NO20031049D0 (no) Syntetiske erytropoese-stimulerende proteiner
GB2338237A (en) In vitro peptide or protein expression library
AU2002306944A1 (en) Spider silk protein encoding nucleic acids, polypeptides, antibodies and method of use thereof
DE69737683D1 (de) Antikörper gegen die ed-b domäne von fibronektin, ihre herstellung und verwendungen
WO2003102157A3 (en) Synthetic antibody phage libraries
EP1712623A3 (de) Selektion von Proteinen unter Verwendung von RNA-protein-fusionen
AU2002351239A1 (en) Antibody to latent membrane proteins and uses thereof
WO2002018948A3 (en) Differentially expressed epitopes and uses thereof
WO2000056901A3 (en) Linear and circular expression elements
DE60137829D1 (de) Menschliche stra6 polypeptide
DE60228603D1 (de) Antigene und vektoren für impfung
AU2001238212A1 (en) Modified fluorescent proteins
WO2001057198A3 (en) Methods of generating protein expression arrays and the use thereof in rapid screening
DK1274853T3 (da) Materialer og fremgangsmåder, der angår immunreaktioner på fusionsproteiner
WO2003020005A3 (en) Lp mammalian proteins; related reagents
ID29405A (id) Protein antigen tumor sart-3 yang baru dan peptida-peptida antigen tumornya
AU2003302133A1 (en) Uses of ble proteins and antibiotics from the bleomycin family
AU2001238064A1 (en) 18477, a human protein kinase and uses therefor
WO2002074906A3 (en) Lp mammalian proteins; related reagents
WO2002027327A3 (en) Rapid profiling of the interactions between a chemical entity and proteins in a given proteome

Legal Events

Date Code Title Description
8364 No opposition during term of opposition